Compare Moderna, Inc. (MRNA) vs State Street PDR S&P Retail ETF (XRT) Price & Performance

Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.

Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.

XRT trades at $88.94, down 0.54% today, with a bullish technical signal from moving averages and neutral oscillators. Support levels are at $87-$88, resistance at $90-$91. The ETF tracks the retail sector, which shows mixed consumer sentiment amid rising energy costs and slowing inflation. Recent retail sales growth has been positive but decelerating, with June up 0.2% after May's 1.0% gain (Census Bureau, June 2026).

Outlook is cautious due to macroeconomic pressures on consumer spending, though the ETF's diversification offers stability. Risks include inflation volatility and weak consumer confidence. Analyst sentiment is mixed, with some downgrades citing headwinds. The technical setup suggests near-term consolidation between support and resistance levels.